Different Doses of Nalbuphine Combined with Dexmedetomidine in Laparoscopic Oophorocystectomy

24 August 2021: Clinical Research

Xiaofen Liu ^ABCDEF , Jie Song ^BCDF , Yang Zhang ^BCDF , Ye Zhang ^BCDF , Xianwen Hu ^CDFG*

DOI: 10.12659/MSM.930197

Med Sci Monit 2021; 27:e930197

Table 5 Hospitalization time and complications in all patients.

Variables	LND, n=55	MND, n=54	HND, n=55	Control, n=55	P value
Hospitalization, days	6.20±1.41^c	6.05±1.54^c	4.33±1.14^a	6.94±1.40^a
Complications, n (%)					0.650
Nausea and vomiting	3 (5.45)	2 (3.70)	2 (3.70)	3 (5.45)
Dizziness and headache	1 (1.82)	1 (1.82)	1 (1.82)	2 (3.70)
Fidgety	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)
Skin Itch	1 (1.82)	0 (0.00)	1 (1.82)	0 (0.00)
^a ^b ^c ^d LND – low-dose nalbuphine and dexmedetomidine; MDN – middle-dose nalbuphine and dexmedetomidine; HND – high-dose nalbuphine and dexmedetomidine.